Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T14:50:37.177Z.
Calculation as of: 2026-10-06T14:50:37.177Z.
Quote observation: 2026-10-06T14:50:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa223cd5a0006a47bd3f11d3634c651a1c818c2f8beb58cb941cded2cdd6eca8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Adial Pharmaceuticals, Inc.
Market Cap
$11.21M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.26M
EV/Sales Ratio
N/A
TTM Avg
2.30x
3Y Avg
2.30x
5Y Avg
5910.26x
Market Cap
$11.31M
EV/Sales Ratio
15.00x
TTM Avg
73.67x
3Y Avg
220.77x
5Y Avg
480.05x
Market Cap
$11.00M
EV/Sales Ratio
N/A
TTM Avg
30.14x
3Y Avg
54.00x
5Y Avg
56.96x
Market Cap
$11.38M
EV/Sales Ratio
9.40x
TTM Avg
63.85x
3Y Avg
37.14x
5Y Avg
37.14x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.21M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.26M | N/A | 2.30x | 2.30x | 5910.26x |
| Biofrontera Inc. (BFRI)vs › | $11.13M | 0.30x | 0.30x | 0.19x | 0.34x |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.31M | 15.00x | 73.67x | 220.77x | 480.05x |
| BioVie Inc. (BIVI)vs › | $11.01M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.98M | 2.06x | 3.91x | 3.91x | 3.91x |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | 30.14x | 54.00x | 56.96x |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.38M | 9.40x | 63.85x | 37.14x | 37.14x |
| Lantern Pharma Inc. (LTRN)vs › | $12.12M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.47M | 0.55x | 0.46x | 0.66x | 0.66x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
